奥格列汀:一种新的长效二肽基肽酶-4抑制剂

Omarigliptin: A new kind of long acting DPP-4 inhibitor

糖尿病是一种以高血糖为特征的代谢性疾病,目前常用的口服降糖药均需要每天服药,给患者带来不便。奥格列汀是一个小分子二肽基肽酶-4(DPP-4)抑制剂,由默克公司研发,主要用于二型糖尿病的治疗,且只需1周服用1次即可,从而提高了患者的顺应性和坚持性,最终提高了治疗效果。介绍了奥格列汀的合成方法、药理学、药物代谢动力学、临床研究等信息,为更好地应用临床与研发类似新药提供依据。

Diabetes is a kind of metabolic disease characterized by hyperglycemia The oral hypoglycemic agents used currently are required to take every day, which brings inconvenience to patients. Omarigliptin is a small molecule DPP-4 （depeptidyl peptidase-4） inhibitor. The drug is developed by the Merck Co, mainly for the treatment of type two diabetes. The drug only need to be taken once a week, so as to improve the patient＇s compliance and adherence, thereby improving the therapeutic effect. This article introduces the information of omarigliptin from the aspects of synthesis, pharmacology, pharmacokinetics, and clinical research, which provides valuable information for pharmaceutical workers.